<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">In patients with breast cancer after Neoadjuvant Chemotherapy...<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">In patients with breast cancer after Neoadjuvant Chemotherapy (NAC), pathological Complete Response (pCR) was associated with better </span><span style="font-family:Verdana;">long-term outcome</span></span><span style="font-family:Verdana;">s</span><span style="font-family:Verdana;">. We here attempted to predict pCR using machine</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> learning. </span><b><span style="font-family:Verdana;">Patients and Methods:</span></b><span style="font-family:Verdana;"> From 2008 to 2017, 1308 breast cancer patients underwent NAC before surgery, of whom 377 patients underwent Cancer</span></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">SCAN</span><sup><span style="font-family:Verdana;">TM</span></sup><span style="font-family:Verdana;"> for gene data. Of 377, 238 were analyzed here, with 139 excluded due to incomplete medical data. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The pCR (-</span></span><span style="font-family:;" "=""><span><span style="font-family:Verdana;">) vs. (+) group had 200 vs. 38 patients. In our predictive model with gene data, the Area Under the </span><span style="font-family:Verdana;">Curve (AUC) of the Receiver Operating Characteristic (ROC) curve was</span><span style="font-family:Verdana;"> 0.909 and accuracy was 0.875. In another model without gene data, the AUC of ROC curve was 0.743 and accuracy was 0.800. We also conducted internal validation with 72 patients undergoing NAC and Cancer</span></span></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">SCAN</span><sup><span style="font-family:Verdana;">TM</span></sup><span style="font-family:Verdana;"> during July 2017 and April 2018. When we applied a 0.4 threshold value, accuracy was </span><span style="font-family:Verdana;">0.806 and 0.778 in </span></span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">predictive model with vs. without gene profiles, </span><span style="font-family:;" "=""><span style="font-family:Verdana;">respec</span><span><span style="font-family:Verdana;">tively. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The present predictive model may be a useful an</span></span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> easy-to-access tool for pCR-prediction in breast cancer patients treated with NAC.</span></span>展开更多
Background Surrogate markers may be used to assess the response to neoadjuvant treatment. The association between HER2 overexpression and favorable response to specific therapy in breast cancer is controversial, and t...Background Surrogate markers may be used to assess the response to neoadjuvant treatment. The association between HER2 overexpression and favorable response to specific therapy in breast cancer is controversial, and the mechanism unclear. The purpose of the study was to evaluate HER2 and topoisomerase Ⅱα (Topo Ⅱα) as candidates for predicting the response to neoadjuvant chemotherapy in breast cancer patients.Methods Between 1999 and 2006, seventy-six breast cancer patients who had received neoadjuvant chemotherapy were studied. Regimens including either CEF (cyclophosphamide, epirubicin, 5-fluorouracil) or CMF (cyclophosphamide, methotrexate, 5-fluorouracil) were given in more than three cycles to this group of patients. Protein expression of HER2 and Topo Ⅱα were determined by immunohistochemistry. The primary endpoint was pathological and clinical response.Results Of 76 primary breast cancer samples, 27 (35.5%) showed overexpression of either HER2 (25%) or Topo Ⅱα protein (10.5%), whereas in 7 tumors (9.2%) both proteins were found to be overexpressed. Ten patients (13.2%) had a clinical complete response and 21 (27.6%) had a clinical partial response. Five women (6.6%) had a pathological complete response, 5 (6.6%) had microscopic residual disease, and 46 (60.5%) had macroscopic residual disease. HER2 and Topo Ⅱα overexpression was significantly associated with a favorable response (P 〈0.001 and P=0.005 respectively).Conclusion Our study suggests that HER2 and Topo Ⅱα overexpression could be predictors of the response to neoadjuvant chemothrapy in both the CEF and CMF arms.展开更多
Background Use of neoadjuvant chemotherapy necessitates assessment of response to cytotoxic drugs.The aim of this research was to investigate the effectiveness of dynamic contrast-enhanced magnetic resonance imaging ...Background Use of neoadjuvant chemotherapy necessitates assessment of response to cytotoxic drugs.The aim of this research was to investigate the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (MRI) for evaluating clinical responses to neoadjuvant chemotherapy in breast cancer patients.Methods We examined patients receiving neoadjuvant chemotherapy for primary breast cancer between October 2007and September 2008.Dynamic contrast-enhanced MRI was used to examine breast tumors prior to and after neoadjuvant chemotherapy.The MRI examination assessed tumors using Response Evaluation Criteria in Solid Tumors (RECIST).The Miller-Payne grading system was used as a histopathological examination to assess the effect of the treatment.We examined the relationship between the results of RECIST and histopathological criteria.In addition,we used time-signal intensity curves (MRI T-SI) to further evaluate the effects of neoadjuvant chemotherapy on tumor response.Results MRI examination of patients completing four three-week anthracycline-taxanes chemotherapy treatment revealed that no patients had complete responses (CR),58 patients had partial responses (PR),29 patients had stable disease (SD),and four with progressive disease (PD).The effectiveness of neoadjuvant chemotherapy (CR + PR) was 63.7% (58/91).The postoperative histopathological evaluations revealed the following:seven G5 (pCR) cases (7.7%),39G4 cases (42.9%),16 G3 cases (17.6%),23 G2 cases (25.3%),and six G1 cases (6.6%).The effectiveness (G5 + G4 +G3) was 68.1% (62/91).MRI T-SI standards classified 53 responding cases,29 stable cases,and nine progressing cases.These results indicated that the treatment was 58.2% effective (53/91) overall.Conclusions Dynamic contrast-enhanced MRI and histopathological standards were highly correlated.Importantly,MRI T-SI evaluation was found to be useful in assessing the clinical effectiveness of neoadjuvant chemotherapy.展开更多
Background Neoadjuvant chemotherapy provides an excellent model for evaluation of potential predictive factors. The objective of this study was to evaluate the predictive value of different biological factors in breas...Background Neoadjuvant chemotherapy provides an excellent model for evaluation of potential predictive factors. The objective of this study was to evaluate the predictive value of different biological factors in breast cancer patients treated with neoadjuvant taxane and anthracycline chemotherapy. Methods One hundred and thirty-five patients treated with 4 cycles of neoadjuvant taxanes and anthracycline were included in this retrospective study. Using pretreatment biopsy materials, immunohistochemical studies were performed for estrogen receptor (ER), progesterone receptor (PgR), HER-2, Ki-67 and p53 protein expression. The associations among biological markers and clinical and pathological complete response (pCR) were analyzed. Results The overall clinical response was 86%, including 33% clinical complete response (cCR) and 53% clinical partial response. The pCR was just 17%. In the univariate analysis, only HER-2 overexpression was predictive of cCR to neoadjuvant chemotherapy (P=-0.018). No significant associations between other biological factors and cCR were found. Absence of ER, PgR expression and overexpression of HER-2 were predictive of the pCR (P=0.002, 0.001, 0.01, respectively). Ki-67 and p53 failed to show an association with pCR. In multivariate analysis, overexpression of HER-2 remained as an independent variable in predicting the cCR (P=-0.021). However, negative ER was the only parameter that maintained statistical significance in predicting the pCR (P=-0.001). Conclusions Patients with overexpression of HER-2 and negative hormonal receptor status are much more likely to respond to neoadjuvant taxane and anthracycline chemotherapy than those with the opposite characteristics. These factors could serve as predictive markers for this regimen.展开更多
文摘<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">In patients with breast cancer after Neoadjuvant Chemotherapy (NAC), pathological Complete Response (pCR) was associated with better </span><span style="font-family:Verdana;">long-term outcome</span></span><span style="font-family:Verdana;">s</span><span style="font-family:Verdana;">. We here attempted to predict pCR using machine</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> learning. </span><b><span style="font-family:Verdana;">Patients and Methods:</span></b><span style="font-family:Verdana;"> From 2008 to 2017, 1308 breast cancer patients underwent NAC before surgery, of whom 377 patients underwent Cancer</span></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">SCAN</span><sup><span style="font-family:Verdana;">TM</span></sup><span style="font-family:Verdana;"> for gene data. Of 377, 238 were analyzed here, with 139 excluded due to incomplete medical data. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The pCR (-</span></span><span style="font-family:;" "=""><span><span style="font-family:Verdana;">) vs. (+) group had 200 vs. 38 patients. In our predictive model with gene data, the Area Under the </span><span style="font-family:Verdana;">Curve (AUC) of the Receiver Operating Characteristic (ROC) curve was</span><span style="font-family:Verdana;"> 0.909 and accuracy was 0.875. In another model without gene data, the AUC of ROC curve was 0.743 and accuracy was 0.800. We also conducted internal validation with 72 patients undergoing NAC and Cancer</span></span></span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">SCAN</span><sup><span style="font-family:Verdana;">TM</span></sup><span style="font-family:Verdana;"> during July 2017 and April 2018. When we applied a 0.4 threshold value, accuracy was </span><span style="font-family:Verdana;">0.806 and 0.778 in </span></span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">predictive model with vs. without gene profiles, </span><span style="font-family:;" "=""><span style="font-family:Verdana;">respec</span><span><span style="font-family:Verdana;">tively. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The present predictive model may be a useful an</span></span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> easy-to-access tool for pCR-prediction in breast cancer patients treated with NAC.</span></span>
文摘Background Surrogate markers may be used to assess the response to neoadjuvant treatment. The association between HER2 overexpression and favorable response to specific therapy in breast cancer is controversial, and the mechanism unclear. The purpose of the study was to evaluate HER2 and topoisomerase Ⅱα (Topo Ⅱα) as candidates for predicting the response to neoadjuvant chemotherapy in breast cancer patients.Methods Between 1999 and 2006, seventy-six breast cancer patients who had received neoadjuvant chemotherapy were studied. Regimens including either CEF (cyclophosphamide, epirubicin, 5-fluorouracil) or CMF (cyclophosphamide, methotrexate, 5-fluorouracil) were given in more than three cycles to this group of patients. Protein expression of HER2 and Topo Ⅱα were determined by immunohistochemistry. The primary endpoint was pathological and clinical response.Results Of 76 primary breast cancer samples, 27 (35.5%) showed overexpression of either HER2 (25%) or Topo Ⅱα protein (10.5%), whereas in 7 tumors (9.2%) both proteins were found to be overexpressed. Ten patients (13.2%) had a clinical complete response and 21 (27.6%) had a clinical partial response. Five women (6.6%) had a pathological complete response, 5 (6.6%) had microscopic residual disease, and 46 (60.5%) had macroscopic residual disease. HER2 and Topo Ⅱα overexpression was significantly associated with a favorable response (P 〈0.001 and P=0.005 respectively).Conclusion Our study suggests that HER2 and Topo Ⅱα overexpression could be predictors of the response to neoadjuvant chemothrapy in both the CEF and CMF arms.
文摘Background Use of neoadjuvant chemotherapy necessitates assessment of response to cytotoxic drugs.The aim of this research was to investigate the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (MRI) for evaluating clinical responses to neoadjuvant chemotherapy in breast cancer patients.Methods We examined patients receiving neoadjuvant chemotherapy for primary breast cancer between October 2007and September 2008.Dynamic contrast-enhanced MRI was used to examine breast tumors prior to and after neoadjuvant chemotherapy.The MRI examination assessed tumors using Response Evaluation Criteria in Solid Tumors (RECIST).The Miller-Payne grading system was used as a histopathological examination to assess the effect of the treatment.We examined the relationship between the results of RECIST and histopathological criteria.In addition,we used time-signal intensity curves (MRI T-SI) to further evaluate the effects of neoadjuvant chemotherapy on tumor response.Results MRI examination of patients completing four three-week anthracycline-taxanes chemotherapy treatment revealed that no patients had complete responses (CR),58 patients had partial responses (PR),29 patients had stable disease (SD),and four with progressive disease (PD).The effectiveness of neoadjuvant chemotherapy (CR + PR) was 63.7% (58/91).The postoperative histopathological evaluations revealed the following:seven G5 (pCR) cases (7.7%),39G4 cases (42.9%),16 G3 cases (17.6%),23 G2 cases (25.3%),and six G1 cases (6.6%).The effectiveness (G5 + G4 +G3) was 68.1% (62/91).MRI T-SI standards classified 53 responding cases,29 stable cases,and nine progressing cases.These results indicated that the treatment was 58.2% effective (53/91) overall.Conclusions Dynamic contrast-enhanced MRI and histopathological standards were highly correlated.Importantly,MRI T-SI evaluation was found to be useful in assessing the clinical effectiveness of neoadjuvant chemotherapy.
文摘Background Neoadjuvant chemotherapy provides an excellent model for evaluation of potential predictive factors. The objective of this study was to evaluate the predictive value of different biological factors in breast cancer patients treated with neoadjuvant taxane and anthracycline chemotherapy. Methods One hundred and thirty-five patients treated with 4 cycles of neoadjuvant taxanes and anthracycline were included in this retrospective study. Using pretreatment biopsy materials, immunohistochemical studies were performed for estrogen receptor (ER), progesterone receptor (PgR), HER-2, Ki-67 and p53 protein expression. The associations among biological markers and clinical and pathological complete response (pCR) were analyzed. Results The overall clinical response was 86%, including 33% clinical complete response (cCR) and 53% clinical partial response. The pCR was just 17%. In the univariate analysis, only HER-2 overexpression was predictive of cCR to neoadjuvant chemotherapy (P=-0.018). No significant associations between other biological factors and cCR were found. Absence of ER, PgR expression and overexpression of HER-2 were predictive of the pCR (P=0.002, 0.001, 0.01, respectively). Ki-67 and p53 failed to show an association with pCR. In multivariate analysis, overexpression of HER-2 remained as an independent variable in predicting the cCR (P=-0.021). However, negative ER was the only parameter that maintained statistical significance in predicting the pCR (P=-0.001). Conclusions Patients with overexpression of HER-2 and negative hormonal receptor status are much more likely to respond to neoadjuvant taxane and anthracycline chemotherapy than those with the opposite characteristics. These factors could serve as predictive markers for this regimen.